2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(12)61766-8.pdf

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

ABI
: ankle–brachial index
ACCORD
: Action to Control Cardiovascular Risk in Diabetes
ADVANCE
: Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation
AGREE
: Appraisal of Guidelines Research and Evaluation
AHA
: American Heart Association
apoA1
: apolipoprotein A1
apoB
: apolipoprotein B
CABG
: coronary artery bypass graft surgery
CARDS
: Collaborative AtoRvastatin Diabetes Study
CCNAP
: Council on Cardiovascular Nursing and Allied Professions
CHARISMA
: Clopidogrel for High Athero-thrombotic Risk and Ischemic Stabilisation, Management, and Avoidance
CHD
: coronary heart disease
CKD
: chronic kidney disease
COMMIT
: Clopidogrel and Metoprolol in Myocardial Infarction Trial
CRP
: C-reactive protein
CURE
: Clopidogrel in Unstable Angina to Prevent Recurrent Events
CVD
: cardiovascular disease
DALYs
: disability-adjusted life years
DBP
: diastolic blood pressure
DCCT
: Diabetes Control and Complications Trial
ED
: erectile dysfunction
eGFR
: estimated glomerular filtration rate
EHN
: European Heart Network
EPIC
: European Prospective Investigation into Cancer and Nutrition
EUROASPIRE
: European Action on Secondary and Primary Prevention through Intervention to Reduce Events
GFR
: glomerular filtration rate
GOSPEL
: Global Secondary Prevention Strategies to Limit Event Recurrence After MI
GRADE
: Grading of Recommendations Assessment, Development and Evaluation
HbA1c
: glycated haemoglobin
HDL
: high-density lipoprotein
HF-ACTION
: Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing
HOT
: Hypertension Optimal Treatment Study
HPS
: Heart Protection Study
HR
: hazard ratio
hsCRP
: high-sensitivity C-reactive protein
HYVET
: Hypertension in the Very Elderly Trial
ICD
: International Classification of Diseases
IMT
: intima-media thickness
INVEST
: International Verapamil SR/Trandolapril
JTF
: Joint Task Force
LDL
: low-density lipoprotein
Lp(a)
: lipoprotein(a)
LpPLA2
: lipoprotein-associated phospholipase 2
LVH
: left ventricular hypertrophy
MATCH
: Management of Atherothrombosis with Clopidogrel in High-risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke
MDRD
: Modification of Diet in Renal Disease
MET
: metabolic equivalent
MONICA
: Multinational MONItoring of trends and determinants in CArdiovascular disease
NICE
: National Institute of Health and Clinical Excellence
NRT
: nicotine replacement therapy
NSTEMI
: non-ST elevation myocardial infarction
ONTARGET
: Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial
OSA
: obstructive sleep apnoea
PAD
: peripheral artery disease
PCI
: percutaneous coronary intervention
PROactive
: Prospective Pioglitazone Clinical Trial in Macrovascular Events
PWV
: pulse wave velocity
QOF
: Quality and Outcomes Framework
RCT
: randomized clinical trial
RR
: relative risk
SBP
: systolic blood pressure
SCORE
: Systematic Coronary Risk Evaluation Project
SEARCH
: Study of the Effectiveness of Additional Reductions in Cholesterol and
SHEP
: Systolic Hypertension in the Elderly Program
STEMI
: ST-elevation myocardial infarction
SU.FOL.OM3
: SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acids
Syst-Eur
: Systolic Hypertension in Europe
TNT
: Treating to New Targets
UKPDS
: United Kingdom Prospective Diabetes Study
VADT
: Veterans Affairs Diabetes Trial
VALUE
: Valsartan Antihypertensive Long-term Use
VITATOPS
: VITAmins TO Prevent Stroke
VLDL
: very low-density lipoprotein
WHO
: World Health Organization

### 1.1 Introduction

Atherosclerotic cardiovascular disease (CVD) is a chronic disorder developing insidiously throughout life and usually progressing to an advanced stage by the time symptoms occur. It remains the major cause of premature death in Europe, even though CVD mortality has …

/pdf/european-guidelines-on-cardiovascular-disease-prevention-in-4z4nw4311i.pdf

European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)

WRITING GROUP MEMBERS Emelia J. Benjamin, MD, SCM, FAHA Michael J. Blaha, MD, MPH Stephanie E. Chiuve, ScD Mary Cushman, MD, MSc, FAHA Sandeep R. Das, MD, MPH, FAHA Rajat Deo, MD, MTR Sarah D. de Ferranti, MD, MPH James Floyd, MD, MS Myriam Fornage, PhD, FAHA Cathleen Gillespie, MS Carmen R. Isasi, MD, PhD, FAHA Monik C. Jiménez, ScD, SM Lori Chaffin Jordan, MD, PhD Suzanne E. Judd, PhD Daniel Lackland, DrPH, FAHA Judith H. Lichtman, PhD, MPH, FAHA Lynda Lisabeth, PhD, MPH, FAHA Simin Liu, MD, ScD, FAHA Chris T. Longenecker, MD Rachel H. Mackey, PhD, MPH, FAHA Kunihiro Matsushita, MD, PhD, FAHA Dariush Mozaffarian, MD, DrPH, FAHA Michael E. Mussolino, PhD, FAHA Khurram Nasir, MD, MPH, FAHA Robert W. Neumar, MD, PhD, FAHA Latha Palaniappan, MD, MS, FAHA Dilip K. Pandey, MBBS, MS, PhD, FAHA Ravi R. Thiagarajan, MD, MPH Mathew J. Reeves, PhD Matthew Ritchey, PT, DPT, OCS, MPH Carlos J. Rodriguez, MD, MPH, FAHA Gregory A. Roth, MD, MPH Wayne D. Rosamond, PhD, FAHA Comilla Sasson, MD, PhD, FAHA Amytis Towfighi, MD Connie W. Tsao, MD, MPH Melanie B. Turner, MPH Salim S. Virani, MD, PhD, FAHA Jenifer H. Voeks, PhD Joshua Z. Willey, MD, MS John T. Wilkins, MD Jason HY. Wu, MSc, PhD, FAHA Heather M. Alger, PhD Sally S. Wong, PhD, RD, CDN, FAHA Paul Muntner, PhD, MHSc On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics—2017 Update

Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association

Jeffrey L. Anderson, MD, FACC, FAHA, Chair 

Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect 

Nancy M. Albert, PhD, RN, FAHA

Biykem Bozkurt, MD, PhD, FACC, FAHA

Ralph G. Brindis, MD, MPH, MACC

Mark A. Creager, MD, FACC, FAHA[#][1]

Lesley H. Curtis, PhD, FAHA

David DeMets, PhD[#][1]

Robert A

/pdf/2014-aha-acc-hrs-guideline-for-the-management-of-patients-1v8ficsqox.pdf

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

Machine Learning (ML) methods have become important for enhancing the performance of decision-support predictive models. However, class imbalance is one of the main challenges for developing ML models, because it may bias the learning process and the model generalization ability. In this paper, we consider oversampling methods for generating synthetic categorical clinical data aiming to improve the predictive performance in ML models, and the identification of risk factors for cardiovascular diseases (CVDs). We performed a comparative study of several categorical synthetic data generation methods, including Synthetic Minority Oversampling Technique Nominal (SMOTEN), Tabular Variational Autoencoder (TVAE) and Conditional Tabular Generative Adversarial Networks (CTGANs). Then, we assessed the impact of combining oversampling strategies and linear and nonlinear supervised ML methods. Lastly, we conducted a post-hoc model interpretability based on the importance of the risk factors. Experimental results show the potential of GAN-based models for generating high-quality categorical synthetic data, yielding probability mass functions that are very close to those provided by real data, maintaining relevant insights, and contributing to increasing the predictive performance. The GAN-based model and a linear classifier outperform other oversampling techniques, improving the area under the curve by 2%. These results demonstrate the capability of synthetic data to help with both determining risk factors and building models for CVD prediction.

/pdf/evaluation-of-synthetic-categorical-data-generation-u15zbd19.pdf

Evaluation of Synthetic Categorical Data Generation Techniques for Predicting Cardiovascular Diseases and Post-Hoc Interpretability of the Risk Factors


 
 
 Atrial fibrillation (AF) and heart failure (HF) are common diseases that often co-exist and substantially impact both morbidity, mortality, and quality of life. Although there has been an increasing amount of research on HF in AF patients, there is limited knowledge on the association of AF subtypes (paroxysmal/persistent, permanent) with HF in women and men.
 
 
 
 To explore the sex-specific association between incident AF subtypes and HF risk factors and mortality in AF participants in a general population.
 
 
 
 A total of 14,798 women and 13,197 men aged 25 years and older were enrolled from 1994 to 2008 and followed up for incident AF and HF through 2016. Cox proportional hazards regression analysis was conducted to provide sex- and AF subtype-specific hazard ratios (HRs) for the risk of HF, risk factors for HF and joint influence on mortality when AF precedes HF. Participants without AF and HF were used as reference. In the analysis of risk factors for HF we included only those who developed AF, and the follow-up period started at the date of first detected AF. Models were adjusted for systolic blood pressure, body mass index (BMI), total cholesterol, current smoking, physical activity, and history of myocardial infarction, angina pectoris, stroke, and diabetes mellitus, as well as age, with age as the time scale in the regression models.
 
 
 
 Over a median follow-up of 21.6 years, incident AF occurred in 856 women (471 with paroxysmal/persistent AF and 385 with permanent AF) and 1,036 men (587 with paroxysmal/persistent AF and 449 with permanent AF). Incident HF occurred in 761 women and 930 men. In both sexes, there was an increased risk of HF when AF was present. For permanent AF, women had a significantly higher risk of HF than men (HR 10.50, 95% CI 8.72–12.66 vs. HR 8.11, 95% CI 6.81–9.67). Permanent AF, current smoking, and prevalent myocardial infarction were significant risk factors for HF in AF participants in both sexes, while hypertension was only associated with increased risk of HF in women and BMI and prevalent stroke in men. Higher physical activity level was associated with reduced risk of AF in both sexes. The risk of death increased when HF succeeded AF. For women the risk of mortality was higher for permanent AF (HR 3.83, 95% CI 3.19–4.61 vs. HR 2.98, 95% CI 2.34–3.80), while in men it was highest for paroxysmal/persistent AF (HR 3.67, 95% CI 2.94–4.58 vs. HR 2.91, 95% CI 2.37–3.57), but there was no significant difference between sexes.
 
 
 
 All AF subtypes were associated with an increased risk of HF in both sexes. For permanent AF, women had a significantly higher risk than men. Several risk factors for HF in AF participants were similar between sexes. However, hypertension was only a risk factor in women, whereas BMI and prevalent stroke were only risk factors in men. In AF participants, subsequent development of HF was associated with increased mortality in both sexes.
 
 
 
 Type of funding sources: Public Institution(s). Main funding source(s): UiT The Arctic University of Norway


/pdf/risk-factors-and-prognosis-for-heart-failure-in-atrial-34sbp9l9.pdf

Risk factors and prognosis for heart failure in atrial fibrillation subtypes in women and men

Background The initial presentation to coronary angiography and extent of coronary artery disease (CAD) vary greatly among patients, from ischemia with no obstructive CAD to myocardial infarction w...

https://www.ahajournals.org/doi/pdf/10.1161/JAHA.121.021291

Low Pain Tolerance Is Associated With Coronary Angiography, Coronary Artery Disease, and Mortality: The Tromsø Study.

/pdf/pcsk9-hemmere-pa-bla-resept-for-hvem-3w3k5bip.pdf

Maja-Lisa Løchen

Papers

Evaluation of Synthetic Categorical Data Generation Techniques for Predicting Cardiovascular Diseases and Post-Hoc Interpretability of the Risk Factors

Risk factors and prognosis for heart failure in atrial fibrillation subtypes in women and men

Low Pain Tolerance Is Associated With Coronary Angiography, Coronary Artery Disease, and Mortality: The Tromsø Study.

PCSK9-hemmere på blå resept for hvem?

Personalised cardiovascular disease prevention in the new guidelines.